Avant Proteins Winding Up: Not an Isolated Failure, But a Structural Correction

Singapore—February 2026. Avant Proteins, Asia’s first cultivated fish company, is voluntarily winding up its Singapore operations. It joins Eat Just (paused production) and Shiok Meats (merged) as the third novel food firm to scale back in the Republic since 2020.

This is not an isolated incident. It is a structural correction.

Using peer-reviewed frameworks from the NIH Entrepreneurial Ecosystem Review and Oxford Academic Global Value Chain Analysis, we break down what went wrong—and what surviving startups must do now.

---

1. Impact on Startups: The End of “Proof of Concept”

The "funding winter" is now quantified. Sector investment fell from $989M (2021) to $65M (2025) .

✅ Capital Flight to Later-Stage

Investors are abandoning pre-revenue, CAPEX-heavy models. Avant, Meatable, and Believer Meats all secured regulatory access—but failed to secure follow-on funding. Immediate unit economics are now the only KPI.

✅ Strategic Pivot or Die

The “100% cultivated” burger is dead.

· Ants Innovate (Singapore) succeeded by reducing animal cell content to <3% using A*STAR’s SMILE technology, achieving cost parity.

· Evergreen Connect (fka Omeat) raised $6M in February 2026—specifically for blended beef.

✅ Consolidation Imperative

Going it alone is no longer viable. Parima (Gourmey+Vital Meat) verified costs under €7/kg by consolidating IP and cross-species platforms.

---

2. Impact on Research: Open Collaboration Meets Strategic Risk

Avant’s closure severs the applied pipeline from A*STAR’s Bioprocessing Technology Institute (BTI) to commercial bioreactors. While the collaboration “concluded as planned,” the Woodlands scale-up data is now lost to the public domain.

🔬 Positive Spillover: The “SCiFi Model”

When startups fail, IP sometimes reverts to the public good. The Good Food Institute acquired SCiFi Foods’ cell lines and donated them to Tufts University, saving academia “millions” in R&D costs.

🧪 Talent Drain

Scientists who moved from academia to industry via A*STAR secondments now face displacement—potentially resetting Singapore’s human capital ecosystem.

---

3. Strategic Errors:

Applying Global Value Chain (GVC) and Entrepreneurial Ecosystem (EE) frameworks, Avant made three fatal miscalculations:

A. Governance & Power: The Producer-Driven Trap

Avant attempted to control the entire chain—R&D, production, skincare, retail.

Peer-reviewed insight: The sector is shifting to buyer-driven governance.

✅ Survivors act as B2B ingredients suppliers. Vow and Evergreen Connect leverage incumbent distribution. Avant remained a standalone B2C aspirant—a capital structure that is now fatal.

B. Technology & Capital Efficiency: Scale Mismatch

Academic reviews confirm: while 50L+ bioreactors are achievable, “industrial translation is still limited.”

✅ Parima succeeded via growth factor–free, food-safe feed, directly addressing COGS.

❌ Avant did not publicly demonstrate breakthrough media cost reductions. The <$10/kg benchmark remains elusive.

C. Market Positioning: The “How Low Can You Go?” Question

International Journal of Food Science and Technology frames the critical economic question as animal cell percentage.

✅ Vow sells novelty—Japanese quail foie gras. No conventional comparator exists, allowing premium pricing.

❌ Avant pursued commodity fish fillets and maw, competing directly with cheap conventional alternatives.

---

Conclusion: The New Rulebook for Cultivated Meat

Avant’s exit wounds Singapore’s “first-mover” narrative. But it accelerates sector maturation.

For startups:

✅ B2B ingredients

✅ Hybrid ratios

✅ CAPEX-light partnerships

For researchers:

The loss is real. But the recycling of failed startup IP into open-source academia (the US SCiFi model) presents a new, unintended channel for progress.